Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 3
2013 5
2014 4
2015 2
2016 6
2017 4
2018 4
2019 3
2020 2
2021 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial.
Ji Y, Chen S, Yang K, Zhang X, Zhou J, Li L, Xiang B, Qiu T, Dai S, Jiang X, Lu G, Qiu L, Kong F, Zhang Y. Ji Y, et al. JAMA Otolaryngol Head Neck Surg. 2021 Jul 1;147(7):599-607. doi: 10.1001/jamaoto.2021.0454. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33856430 Free PMC article. Clinical Trial.
IMPORTANCE: Propranolol has become the first-line therapy for problematic infantile hemangiomas (IHs) that require systemic therapy. ...OBJECTIVE: To compare the efficacy and safety of propranolol vs atenolol in infants (between age 5 and …
IMPORTANCE: Propranolol has become the first-line therapy for problematic infantile hemangiomas (IHs) that require syst …
Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population.
Fu R, Zou Y, Wu Z, Jin P, Cheng J, Bai H, Huang M, Huan X, Yuan H. Fu R, et al. Sci Rep. 2023 Apr 12;13(1):5956. doi: 10.1038/s41598-023-33105-2. Sci Rep. 2023. PMID: 37046020 Free PMC article.
Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking. ...The observed adverse effects were majorit …
Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical …
Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital.
Volonté M, Codazzi AC, Davidovich S, Apicella A, Isoletta E, Barruscotti S, Massa M, Silvestri A, Marseglia GL, Brazzelli V. Volonté M, et al. Eur J Dermatol. 2023 Jun 1;33(3):265-269. doi: 10.1684/ejd.2023.4484. Eur J Dermatol. 2023. PMID: 37594334
BACKGROUND: Propranolol is currently considered the first-line therapy for problematic infantile hemangiomas (IH), the most common benign vascular neoplasm of infancy. ...CONCLUSION: Propranolol showed high efficacy in terms of safety profile an …
BACKGROUND: Propranolol is currently considered the first-line therapy for problematic infantile hemangiomas (IH), the …
Oral atenolol compared to oral propranolol for infantile hemangioma.
Meza Viteri V, Aranibar L. Meza Viteri V, et al. Medwave. 2023 Dec 7;23(11):e2753. doi: 10.5867/medwave.2023.11.2753. Medwave. 2023. PMID: 38061014 English, Spanish.
INTRODUCTION: Infantile hemangioma is the most frequent benign vascular tumor in childhood, with an incidence of 3 to 10%. ...The three randomized trials were included in the analysis of this investigation. CONCLUSION: The use of oral atenolol compared with oral …
INTRODUCTION: Infantile hemangioma is the most frequent benign vascular tumor in childhood, with an incidence of 3 to 10%. ... …
Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome.
Olsen GM, Hansen LM, Stefanko NS, Mathes E, Puttgen KB, Tollefson MM, Lauren C, Mancini AJ, McCuaig CC, Frieden IJ, Adams D, Baselga E, Chamlin S, Gupta D, Frommelt P, Garzon MC, Horii K, Klajn J, Maheshwari M, Newell B, Nguyen HL, Nopper A, Powell J, Siegel DH, Drolet BA. Olsen GM, et al. JAMA Dermatol. 2020 Feb 1;156(2):186-190. doi: 10.1001/jamadermatol.2019.3839. JAMA Dermatol. 2020. PMID: 31825455 Free PMC article.
OBJECTIVE: To assess the incidence of adverse events among patients with PHACE syndrome receiving oral propranolol for infantile hemangioma. DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective cohort study assessed the incidence of adverse event …
OBJECTIVE: To assess the incidence of adverse events among patients with PHACE syndrome receiving oral propranolol for infantile …
Cardiac side effects of propranolol in infants treated for infantile haemangiomas.
Maliqari N, Duka E, Kuneshka L. Maliqari N, et al. Cardiol Young. 2023 Dec;33(12):2616-2620. doi: 10.1017/S1047951123000847. Epub 2023 Apr 20. Cardiol Young. 2023. PMID: 37078179
OBJECTIVES: This study aims to add proof to the safety profile of propranolol as first-line choice in treating infantile haemangiomas, in particular related to its cardiac side effects the main hindering reason for parents and physicians to start and comply w …
OBJECTIVES: This study aims to add proof to the safety profile of propranolol as first-line choice in treating infantile …
The role of propranolol in the treatment of infantile hemangioma.
Laranjo S, Costa G, Paramés F, Freitas I, Martins JD, Trigo C, Pinto FF. Laranjo S, et al. Rev Port Cardiol. 2014 May;33(5):289-95. doi: 10.1016/j.repc.2013.10.018. Epub 2014 Jun 4. Rev Port Cardiol. 2014. PMID: 24906291 Free article.
INTRODUCTION: Infantile hemangioma (IH) is one of the most common childhood tumors. ...OBJECTIVE: To prospectively assess the efficacy and safety of propranolol in children with infantile hemangioma. METHODS: We performed a prospective an …
INTRODUCTION: Infantile hemangioma (IH) is one of the most common childhood tumors. ...OBJECTIVE: To prospectively assess the …
Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.
Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L, MacLellan-Tobert S, Mancini AJ, Metry D, Puttgen KB, Seefeldt M, Sidbury R, Ward KM, Blei F, Baselga E, Cassidy L, Darrow DH, Joachim S, Kwon EK, Martin K, Perkins J, Siegel DH, Boucek RJ, Frieden IJ. Drolet BA, et al. Pediatrics. 2013 Jan;131(1):128-40. doi: 10.1542/peds.2012-1691. Epub 2012 Dec 24. Pediatrics. 2013. PMID: 23266923 Free PMC article. Review.
Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities …
Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety mon …
Interventions for infantile haemangiomas of the skin.
Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H, Arevalo-Rodriguez I. Novoa M, et al. Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD006545. doi: 10.1002/14651858.CD006545.pub3. Cochrane Database Syst Rev. 2018. PMID: 29667726 Free PMC article. Review.
Although there were more short- or long-term general adverse effects (such as severe diarrhoea, lethargy, and loss of appetite) in the oral propranolol group, there was no evidence of a difference between groups (RR 7.00, 95% CI 0.40 to 123.35; 1 study; 26 participa …
Although there were more short- or long-term general adverse effects (such as severe diarrhoea, lethargy, and loss of appetite) in th …
39 results